Compare Chevron Corp (CVX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Medpace Holdings Inc — how do they compare? Chevron Corp trades at $179.68 (market cap $361.99B), while Medpace Holdings Inc trades at $531.68 (market cap $15.31B). The key difference: Chevron Corp is far larger — about 23.6× Medpace Holdings Inc's market cap, and Chevron Corp pays a 3.92% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| CVX | MEDP | |
|---|---|---|
Market Cap | $361.99B | $15.31B |
Volume | 9,807,834 | — |
Sector | Energy | Technology |
52-Week High | $211.14 | $620.59 |
52-Week Low | $146.72 | $308.88 |
Enterprise Value | $402.09B | $14.78B |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $182.21, up 3.29% on the day, with bullish technical signals from moving averages and ADX indicators. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.41 surpassing the $1.00 estimate. The company maintains strong operating cash flow of $33.94 billion in 2025 and announced a $13.8 billion investment in Argentina's Vaca Muerta shale project, signaling growth commitment.
The outlook remains positive with a consensus price target of $207.56, implying 13.9% upside. High oil prices and strategic expansions support growth, but declining profit margins and geopolitical tensions pose risks. Analyst sentiment is strongly bullish with 62% buy ratings, though investors should monitor debt levels, which rose to 12.35% of assets in 2025.
MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
